Related Experiment Video
Updated: Jul 7, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Mechanisms of cell death induced by 2-chloroadenosine in leukemic B-cells
Laurent Bastin-Coyette1, Caroline Smal, Sabine Cardoen
1de Duve Institute, Université catholique de Louvain, B-1200 Brussels, Belgium.
Abstract:
2-chloroadenosine (2-CAdo) is an adenosine deaminase-resistant analogue of adenosine, widely used as an adenosine receptor agonist. This compound has been shown to induce apoptosis in several cell types either via activation of adenosine receptors or via intracellular metabolism. However, the molecular mechanisms of 2-CAdo-induced apoptosis are unclear. Here, we analyzed the effects of 2-CAdo in the leukemia cell line EHEB. 2-CAdo was found to induce apoptosis in EHEB cells, as shown by caspase-3 activation, DNA fragmentation, poly(ADP-ribose) polymerase (PARP) cleavage and phosphatidylserine exposure. Cytotoxicity of 2-CAdo was completely suppressed by 5-iodotubercidin, an adenosine kinase inhibitor, indicating that apoptosis induced by 2-CAdo was the result of its intracellular metabolism. Accordingly, we found that 2-CAdo was efficiently converted into 2-chloroATP. In parallel, a decrease of intracellular ATP concentration as well as a general inhibition of macromolecular synthesis, involving DNA, RNA and protein synthesis, was observed. Moreover, 2-CAdo induced cytochrome c release into the cytosol, indicating activation of the intrinsic pathway of apoptosis. This was found associated with a decline in Mcl-1 protein level and p53-independent. Inhibition of AMP deaminase by coformycin markedly prevented ATP depletion, and also significantly reduced 2-CAdo cytotoxicity and caspase-3 activation. In conclusion, our data show that intracellular metabolism of 2-CAdo can lead to activation of the intrinsic pathway of apoptosis and that ATP depletion, in addition to the accumulation of the triphosphate analogue, contributes to 2-CAdo-induced apoptosis.
Insights
2-chloroadenosine (2-CAdo) triggers leukemia cell death through intracellular metabolism, leading to ATP depletion and apoptosis. This study clarifies the molecular mechanisms of 2-CAdo-induced cell death.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- 2-chloroadenosine (2-CAdo) is an adenosine analogue used as an adenosine receptor agonist.
- 2-CAdo induces apoptosis via adenosine receptor activation or intracellular metabolism, but mechanisms are unclear.
Purpose of the Study:
- To elucidate the molecular mechanisms of 2-chloroadenosine (2-CAdo)-induced apoptosis in EHEB leukemia cells.
Main Methods:
- Assessed apoptosis markers (caspase-3 activation, DNA fragmentation, PARP cleavage, phosphatidylserine exposure).
- Utilized adenosine kinase inhibitor (5-iodotubercidin) and AMP deaminase inhibitor (coformycin).
- Measured intracellular ATP levels, macromolecular synthesis, and cytochrome c release.
Main Results:
- 2-CAdo induced apoptosis in EHEB cells, dependent on intracellular metabolism via conversion to 2-chloroATP.
- Apoptosis involved ATP depletion, inhibited macromolecular synthesis, Mcl-1 downregulation, and cytochrome c release (intrinsic pathway).
- Inhibition of AMP deaminase partially prevented ATP depletion and reduced 2-CAdo cytotoxicity.
Conclusions:
- Intracellular metabolism of 2-CAdo activates the intrinsic apoptosis pathway in leukemia cells.
- Both ATP depletion and accumulation of the 2-chloroATP analogue contribute to 2-CAdo-induced apoptosis.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
